Simplex Trading
KROS icon

Simplex Trading’s Keros Therapeutics KROS Stock Holding History

Simplex Trading’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-58,700
Closed -$648K – 9838
2026
Q1 		$648K Buy
58,700
+49,800
+560% +$769K ﹤0.01% 2966
2025
Q4 		$181K Sell
8,900
-52,600
-86% -$923K ﹤0.01% 4328
2025
Q3 		$972K Sell
61,500
-83,500
-58% -$1.23M ﹤0.01% 3076
2025
Q2 		$1.94M Buy
145,000
+11,900
+9% +$161K ﹤0.01% 2145
2025
Q1 		$1.36M Buy
133,100
+123,000
+1,218% +$1.43M ﹤0.01% 2410
2024
Q4 		$159K Buy
10,100
+10,000
+10,000% +$520K ﹤0.01% 4733
2024
Q3 		$5K Hold
100
– – ﹤0.01% 7621
2024
Q2 		$4K Buy
+100
New +$5.37K ﹤0.01% 8000
2024
Q1 		– Sell
-100
Closed -$3K – 9368
2023
Q4 		$3K Buy
+100
New +$3.14K ﹤0.01% 8103
2023
Q1 		– Sell
-100
Closed -$4K – 9606
2022
Q4 		$4K Hold
100
– – ﹤0.01% 8217
2022
Q3 		$3K Buy
+100
New +$3.47K ﹤0.01% 9106
2022
Q2 		– Sell
-100
Closed -$5K – 10543
2022
Q1 		$5K Hold
100
– – ﹤0.01% 9418
2021
Q4 		$5K Buy
+100
New +$4.99K ﹤0.01% 9530

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Simplex Trading's KROS Position: Q2 2026 in Review

Simplex Trading sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 22,288 shares — an estimated $248K sold.

Simplex Trading first reported a position in KROS in Q2 2022 and held it in 8 quarters. The position peaked at $1.21M in Q2 2025. 133 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Simplex Trading reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 22,288 Keros Therapeutics shares in Q2 2026, an estimated $248K.
  • Simplex Trading first reported a position in Keros Therapeutics in Q2 2022 and held it in 8 quarters.
  • Simplex Trading's Keros Therapeutics position peaked at $1.21M in Q2 2025.
  • 133 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.